Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Brett Cucchiara et al, published in Stroke:
”Exploring advances in antithrombotic therapy for noncardioembolic ischemic stroke: The OCEANIC-STROKE trial marks a significant development with its dual-pathway inhibition approach using asundexian alongside antiplatelet therapy.
Current evidence highlights the efficacy of antiplatelet monotherapy and, in certain scenarios, the superiority of dual-antiplatelet therapy shortly after an event.
However, the emerging promise of factor XI/XIa inhibitors could revolutionize secondary stroke prevention, potentially enhancing efficacy without increasing bleeding risks.
Dive into the latest findings and what they signify for future treatment directions.”
Title: Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions
Authors: Brett Cucchiara, Jean M. Connors, Alejandro A. Rabinstein, Mukul Sharma
Read the Full Article on Stroke
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 30, 2026, 18:19Deva Nanda TK: A Practical Overview of Dural Sinuses and The Venous Drainage of the Brain
-
Apr 30, 2026, 18:08Amrit Kaur Kaler: The Hidden Genetic Drivers of Thrombosis
-
Apr 30, 2026, 18:06Alejandro González Veliz: The Most Dangerous Mistake After Getting a Stent
-
Apr 30, 2026, 18:03Carmen Ruiz: First Arterial Mechanical Thrombectomy in New Zealand Using the ARTIX System
-
Apr 30, 2026, 17:52Simon Senanu: von Willebrand Disease May Be Missed Despite Normal Tests
-
Apr 30, 2026, 17:20José Antonio García Erce: Why Healthy Older Adults Should Keep Donating Blood?
-
Apr 30, 2026, 17:13Paul Logan: Decoding the Words ‘He’s on blood thinners’
-
Apr 30, 2026, 17:01Jason Andrade: A Decade-Long Quest Proves Early Ablation Halves Persistent AF Burden
-
Apr 30, 2026, 16:56Oliver Maracic: Could Co-Targeting ALK with FAK/PYK2 Help Mitigate the High VTE Burden Seen in ALK with NSCLC